Table: Towa Pharmaceutical - 6-MTH group results
Nov 12 (Reuters)-
Towa Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2024 Sep 30, 2023 Mar 31, 2025
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 123.40 107.40 262.10
(+14.9 pct) (+18.7 pct) (+15.0 pct)
Operating 10.51 7.00 23.30
(+50.1 pct) (+117.5 pct) (+32.0 pct)
Recurring 10.34 10.23 22.70
(+1.0 pct) (+122.0 pct) (-7.3 pct)
Net 6.56 6.95 15.00
(-5.7 pct) (+158.3 pct) (-7.3 pct)
EPS 133.17 yen 141.26 yen 304.72 yen
Ann Div 60.00 yen 60.00 yen
-Q2 div 30.00 yen 30.00 yen
-Q4 div 30.00 yen 30.00 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results